Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Cara Therapeutics Inc (NASDAQ: CARA) was $0.76 for the day, up 10.40% from the previous closing price of $0.68. In other words, the price has increased by $10.40 from its previous closing price. On the day, 0.51 million shares were traded. CARA stock price reached its highest trading level at $0.7669 during the session, while it also had its lowest trading level at $0.681.
Ratios:
Our analysis of CARA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.43 and its Current Ratio is at 4.54. In the meantime, Its Debt-to-Equity ratio is 0.76 whereas as Long-Term Debt/Eq ratio is at 0.76.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on March 08, 2023, Downgraded its rating to Underperform and sets its target price to $6 from $13 previously.
On March 08, 2022, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $17 to $20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 05 ’24 when Terrillion Scott sold 2,753 shares for $0.83 per share. The transaction valued at 2,285 led to the insider holds 88,247 shares of the business.
Goncalves Joana sold 2,753 shares of CARA for $2,285 on Apr 05 ’24. The CHIEF MEDICAL OFFICER now owns 53,365 shares after completing the transaction at $0.83 per share. On Feb 29 ’24, another insider, Posner Christopher, who serves as the PRESIDENT AND CEO of the company, sold 5,834 shares for $0.89 each. As a result, the insider received 5,192 and left with 180,521 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CARA now has a Market Capitalization of 41300996 and an Enterprise Value of -16298080. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.97 while its Price-to-Book (P/B) ratio in mrq is 0.72. Its current Enterprise Value per Revenue stands at -0.777 whereas that against EBITDA is 0.134.
Stock Price History:
The Beta on a monthly basis for CARA is 0.75, which has changed by -0.8151589 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, CARA has reached a high of $4.67, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -8.45%, while the 200-Day Moving Average is calculated to be -45.42%.
Shares Statistics:
CARA traded an average of 629.38K shares per day over the past three months and 324100 shares per day over the past ten days. A total of 54.48M shares are outstanding, with a floating share count of 46.47M. Insiders hold about 15.00% of the company’s shares, while institutions hold 48.30% stake in the company. Shares short for CARA as of 1713139200 were 2606185 with a Short Ratio of 4.14, compared to 1710460800 on 2481772. Therefore, it implies a Short% of Shares Outstanding of 2606185 and a Short% of Float of 5.55.
Earnings Estimates
The dynamic stock of Cara Therapeutics Inc (CARA) is currently attracting attention from 5.0 analysts actively involved in rating its market status.On average, analysts expect EPS of -$0.4 for the current quarter, with a high estimate of -$0.35 and a low estimate of -$0.43, while EPS last year was -$0.49. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.23 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.84 and -$1.23 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$1.02, with 5.0 analysts recommending between -$0.68 and -$1.34.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $3.02M to a low estimate of $300k. As of the current estimate, Cara Therapeutics Inc’s year-ago sales were $6.17MFor the next quarter, 5 analysts are estimating revenue of $1.44M. There is a high estimate of $3.54M for the next quarter, whereas the lowest estimate is $80k.
A total of 5 analysts have provided revenue estimates for CARA’s current fiscal year. The highest revenue estimate was $13.66M, while the lowest revenue estimate was $1.3M, resulting in an average revenue estimate of $5.59M. In the same quarter a year ago, actual revenue was $20.97M
